PepGen Q3 2023 net loss $23.3M; cash $129.5M; FDA clears FREEDOM-DM1 study in US

PepGen Inc.

2023-Q3 EPS reported -$2.49

Net loss of $23.3M for Q3 2023, vs $18.6M in Q3 2022; R&D expenses $20.5M.
Cash and cash equivalents $129.5M as of Sept 30, 2023; runway expected into 2025.
FDA lifted clinical hold on FREEDOM-DM1 Phase 1 study; target doses 5, 10, 20 mg/kg.
FDA granted Orphan Drug Designation to PGN-EDODM1 for myotonic dystrophy type 1.
Anticipates proof-of-concept data from CONNECT1-EDO51 study in mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PepGen Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $23.3 million.

Period: the third quarter ended September 30, 2023
Net income: Net loss was $23.3 million
Result: reported results

Exact text from the filing

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent corporate developments.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.